SLC5A2 and diabetic kidney disease: In particular, sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown strong renoprotective effects that were not seen with previous antidiabetic agents,3, –5 suggesting that mechanisms unrelated to hyperglycemia may be involved in the pathogenesis of DKD.